Revelar Biotherapeutics, Inc. and Twist Bioscience Corporation announced that RBT-0813 binds to and neutralizes the Omicron and Delta variants of SARS-CoV-2 in live virus studies. RBT-0813 is an innovative bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar continues to advance preclinical development of RBT-0813 to submit an Investigational New Drug application (IND) in the first half of 2022 to begin human clinical trials shortly thereafter.

This new in vitro binding and neutralization data has been published on BioRxiv with a peer-reviewed publication of the data planned for early 2022. Binding and kinetic data were generated through Surface Plasmon Resonance (SPR) and independently confirmed by flow cytometry. The live virus plaque-reduction data were generated independently at the Yale School of Medicine in the laboratory of Dr. Akiko Iwasaki using live SARS-CoV-2 virus from ancestral, as well as the Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) variants of concern (VOC) isolated from patient nasopharyngeal specimens.